Phaseline

Targets › NIMO

NIMO: drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 2; Oncology; next expected readout Sep 2027.

Open in Phaseline: the race on NIMO, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Georgetown UniversityBXCL701
Selective immuno-modulating neddylation inhibitor (NIMA) targeting NEDD8-activating enzyme
NIMA, NIMOPhase 2Metastatic Pancreatic Ductal AdenocarcinomaSep 2027

Conditions

Metastatic Pancreatic Ductal Adenocarcinoma (1)

Modalities

mixed (1)

Companies

Georgetown University (1)

Related targets

NIMA (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.